JP2024546999A5 - - Google Patents
Info
- Publication number
- JP2024546999A5 JP2024546999A5 JP2024536179A JP2024536179A JP2024546999A5 JP 2024546999 A5 JP2024546999 A5 JP 2024546999A5 JP 2024536179 A JP2024536179 A JP 2024536179A JP 2024536179 A JP2024536179 A JP 2024536179A JP 2024546999 A5 JP2024546999 A5 JP 2024546999A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- combination according
- diakyn
- taa
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163265521P | 2021-12-16 | 2021-12-16 | |
| US63/265,521 | 2021-12-16 | ||
| PCT/US2022/081862 WO2023115033A2 (en) | 2021-12-16 | 2022-12-16 | Use of dual cytokine fusion proteins comprising il-10 and adoptive cell therapies or bispecific t-cell engagers to treat cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024546999A JP2024546999A (ja) | 2024-12-26 |
| JP2024546999A5 true JP2024546999A5 (https=) | 2025-12-19 |
Family
ID=86773657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024536179A Pending JP2024546999A (ja) | 2021-12-16 | 2022-12-16 | Ｉｌ－１０を含む二重サイトカイン融合物およびがんを処置するための養子細胞療法または二重特異性ｔ細胞エンゲージャー |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230210953A1 (https=) |
| EP (1) | EP4447996A4 (https=) |
| JP (1) | JP2024546999A (https=) |
| KR (1) | KR20240161974A (https=) |
| CN (1) | CN118695868A (https=) |
| AU (1) | AU2022413694A1 (https=) |
| CA (1) | CA3240977A1 (https=) |
| IL (1) | IL313588A (https=) |
| MX (1) | MX2024007404A (https=) |
| WO (1) | WO2023115033A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020212598A1 (en) | 2019-04-19 | 2020-10-22 | Synerkine Pharma B.V. | A fusion protein comprising il13 |
| CA3186753A1 (en) * | 2020-07-20 | 2022-01-27 | John Mumm | Dual cytokine fusion proteins comprising il-10 |
| CA3244604A1 (en) * | 2022-02-22 | 2023-08-31 | Deka Biosciences, Inc. | METHOD FOR REDUCING A BISPECIFIC T LYMPHOCYTE RECRUITER OR A CHIMERICAL ANTIGEN RECEPTOR T LYMPHOCYTE CYTOKINE RELEASE SYNDROME USING INTERLEUKIN 4 OR 10, OR AN ASSOCIATED FUSION PROTEIN |
| CN117327184B (zh) * | 2023-12-01 | 2024-03-05 | 赛奥斯博生物科技(北京)有限公司 | 一种靶向msln的嵌合抗原受体及其应用 |
| WO2026083295A1 (en) * | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5989867A (en) * | 1996-09-23 | 1999-11-23 | Knappe; Andrea | DNA encoding IL-10-like homologue; related reagents |
| MXPA02001417A (es) * | 1999-08-09 | 2002-08-12 | Lexigen Pharm Corp | Complejos multiples de citosina-anticuerpo. |
| US20200306375A1 (en) * | 2017-02-22 | 2020-10-01 | Aleta Biotherapeutics Inc. | Compositions and methods for tumor transduction |
| CN121652287A (zh) * | 2019-03-06 | 2026-03-13 | 德卡生物科学公司 | Il-10变体分子和治疗炎性疾病和肿瘤的方法 |
| CA3186753A1 (en) * | 2020-07-20 | 2022-01-27 | John Mumm | Dual cytokine fusion proteins comprising il-10 |
-
2022
- 2022-12-16 US US18/067,535 patent/US20230210953A1/en active Pending
- 2022-12-16 CA CA3240977A patent/CA3240977A1/en active Pending
- 2022-12-16 CN CN202280091741.8A patent/CN118695868A/zh active Pending
- 2022-12-16 JP JP2024536179A patent/JP2024546999A/ja active Pending
- 2022-12-16 IL IL313588A patent/IL313588A/en unknown
- 2022-12-16 AU AU2022413694A patent/AU2022413694A1/en active Pending
- 2022-12-16 KR KR1020247023470A patent/KR20240161974A/ko active Pending
- 2022-12-16 WO PCT/US2022/081862 patent/WO2023115033A2/en not_active Ceased
- 2022-12-16 MX MX2024007404A patent/MX2024007404A/es unknown
- 2022-12-16 EP EP22908772.1A patent/EP4447996A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Myers et al. | Exploring the NK cell platform for cancer immunotherapy | |
| Fabian et al. | The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy | |
| Pinto et al. | Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers | |
| JP2024546999A5 (https=) | ||
| TWI899054B (zh) | 治療癌症及增強ｔ細胞重定向治療劑之功效的方法（一） | |
| Xu et al. | Retargeting T cells to GD2 pentasaccharide on human tumors using bispecific humanized antibody | |
| Huehls et al. | Bispecific T‐cell engagers for cancer immunotherapy | |
| Qin et al. | Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells | |
| US20220265721A1 (en) | Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells | |
| Thakur et al. | “NextGen” biologics: bispecific antibodies and emerging clinical results | |
| IL313588A (en) | Use of dual cytokine fusion proteins comprising il-10 and adoptive cell therapies or bispecific t-cell engagers to treat cancer | |
| WO2019005641A1 (en) | GUIDING AND NAVIGATION CONTROL PROTEINS AND METHODS OF PRODUCTION AND USE THEREOF | |
| IL312224B1 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| Roselli et al. | CAR-T Engineering: Optimizing Signal Transduction and Effector Mechanisms: E. Roselli et al. | |
| EP4426437A1 (en) | Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies | |
| JP2015527070A5 (https=) | ||
| TWI807077B (zh) | 嵌合抗原受體療法t細胞擴增動力學及其用途 | |
| Zhu et al. | Natural killer cell engagers: from bi‐specific to tri‐specific and tetra‐specific engagers for enhanced cancer immunotherapy | |
| Dhimolea et al. | World bispecific antibody summit, September 27–28, 2011, Boston, MA | |
| Wang et al. | An optimal antitumor response by a novel CEA/CD3 bispecific antibody for colorectal cancers | |
| Long et al. | Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma | |
| Park et al. | Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies | |
| Hambach et al. | Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors | |
| Lum et al. | Activated T-cell and bispecific antibody immunotherapy for high-risk breast cancer bench to bedside | |
| Bartels | T-cell engaging antibodies against new tumor-associated targets |